140 related articles for article (PubMed ID: 38344445)
1. Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.
Song YS; Yang H; Kang B; Cheon J; Kim I; Kim H; Lee WS; Sang YB; Jung S; Lim HY; Gaillard VE; Kim C; Chon HJ
Liver Cancer; 2024 Feb; 13(1):89-98. PubMed ID: 38344445
[TBL] [Abstract][Full Text] [Related]
2. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
[TBL] [Abstract][Full Text] [Related]
3. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year.
Kim Y; Kim JS; Kang B; Kim I; Kim H; Lee WS; Sang YB; Jung S; An C; Kim C; Chon HJ
Cancer Res Treat; 2024 May; ():. PubMed ID: 38810969
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma.
Cheon J; Kim H; Kim HS; Kim CG; Kim I; Kang B; Kim C; Jung S; Ha Y; Chon HJ
Ther Adv Med Oncol; 2023; 15():17588359221148541. PubMed ID: 37705533
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
[TBL] [Abstract][Full Text] [Related]
6. A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis.
Lee SK; Kwon JH; Lee SW; Lee HL; Kim HY; Kim CW; Song DS; Chang UI; Yang JM; Nam SW; Kim SH; Song MJ; Kim JH; Lee A; Yang H; Bae SH; Han JW; Nam H; Sung PS; Jang JW; Choi JY; Yoon SK; Shim DJ; Kim D; Kim M
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686699
[TBL] [Abstract][Full Text] [Related]
7. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
[TBL] [Abstract][Full Text] [Related]
8. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.
Kim BK; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon YE; Chon HJ
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406518
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
Muto H; Kuzuya T; Kawabe N; Ohno E; Funasaka K; Nagasaka M; Nakagawa Y; Miyahara R; Shibata T; Hashimoto S; Katano Y; Hirooka Y
Anticancer Res; 2023 Oct; 43(10):4673-4682. PubMed ID: 37772587
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
Toshida K; Itoh S; Yoshiya S; Nagao Y; Tomino T; Izumi T; Iseda N; Toshima T; Ninomiya M; Yoshizumi T
J Gastroenterol Hepatol; 2024 Mar; 39(3):576-586. PubMed ID: 38084637
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
Cheon J; Yoo C; Hong JY; Kim HS; Lee DW; Lee MA; Kim JW; Kim I; Oh SB; Hwang JE; Chon HJ; Lim HY
Liver Int; 2022 Mar; 42(3):674-681. PubMed ID: 34792284
[TBL] [Abstract][Full Text] [Related]
14. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y
Cancer Med; 2023 Apr; 12(7):7772-7783. PubMed ID: 36518086
[TBL] [Abstract][Full Text] [Related]
15. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
[TBL] [Abstract][Full Text] [Related]
16. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
[TBL] [Abstract][Full Text] [Related]
17. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
[TBL] [Abstract][Full Text] [Related]
19. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]